ArticleHealth science reports2026
Early Changes in Quality of Life and Symptom Burden Following Cancer-Directed Treatment Among Head and Neck Cancer Patients in Bangladesh: Findings From a Prospective Pilot Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Evidence on early quality of life (QoL) outcomes among patients with head and neck cancer (HNC) remains limited in low-resource settings like Bangladesh. This prospective pilot study assessed changes in QoL, functioning, and symptom burden following initiation of cancer-directed treatment (CDT) among patients with HNC in Bangladesh. Methods: A prospective observational pilot study was conducted among 102 consecutively recruited patients with HNC from three public cancer care hospitals located in Dhaka City, Bangladesh. Ninety-one patients were reached at follow-up, of whom 57 completed QoL assessment following a mean of 7.4 ± 2.2 weeks of treatment initiation. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30). Linear mixed-model analyses were employed to evaluate longitudinal changes and identify factors associated with QoL outcomes. Results: Of 91 followed-up patients, 16.5% of patients died, and 27.5% did not start CDT, including 25% of survivors. Global quality of life (GQL) among 57 finally assessed patients remained impaired and unchanged over time (β = -0.15, Conclusion: Patients with HNC in Bangladesh experienced an extensive burden of deteriorated QoL, functioning, and increased symptom severity during the early treatment period, besides considerable treatment gaps and mortality. Our findings underscore the necessity of addressing treatment gaps, symptom management, and supportive care. More studies are recommended to support policy implications and implementation regarding early identification, diagnosis, and treatment of HNC in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.